CYCLAREL
Food supplement declared in France, decision dated 28 October 2026
CYCLAREL (Laboratoire Santarel) is a food supplement declared in France. Status: declared in France, may be marketed. 2 rules of use apply to its ingredients (limits and warnings).
- Brand
- Laboratoire Santarel
- Food business operator placing the product on the market
- PBO
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 4 gélules
- Directions for use
- Prendre 2 gélules le matin et 2 gélules le soir avec un grand verre d’eau
- Intended populations
- General population
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, History of breast cancer, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Taking medication, Taking thyroid medication, Children (under 6), Children (under 10)
- Objectives stated by the manufacturer (these are not authorised claims)
- Menstrual cycles
Declaration 378562, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Vitex agnus-castus L. | Fruit | Poudre (de plantes séchées ou broyées) | 400 mg |
| Achillea millefolium L. | Parties aériennes | Extrait sec aqueux | 150 mg |
| Alchemilla vulgaris L. | Parties aériennes | Extrait sec aqueux | 150 mg |
| Silybum marianum (L.) Gaertn. | Graine | Autre extrait sec | 150 mg |
| Brassica oleracea var. italica | Graine | Autre extrait sec | 100 mg |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Sels de magnésium de l'acide citrique | Magnésium | 250 mg | 300 mg |
| Chlorhydrate de pyridoxine | Vitamine B6 | 12 mg | 2 mg |
| Acétate de D-alpha-tocophéryle | Vitamine E | 300 mg | 30 mg |
Additives
E1204
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Ne pas dépasser la dose journalière recommandée. Ce complément alimentaire ne se substitue pas à une alimentation variée et équilibrée et à un mode de vie sain. Tenir hors de la portée des jeunes enfants. A conserver au frais, au sec et à l’abri de la lumière. Réservé à l’adulte. Déconseillé aux femmes enceintes ou allaitantes, en cas de cancer hormono-dépendant (ou d’antécédents personnels ou familiaux de tels cancers), de tumeur hypophysaire à prolactine, ou d’antécédents de troubles hypophysaires et cas d’allergie croisée connue, en particulier aux plantes de la famille des Asteraceae. En cas d'hypothyroïdie ou de traitement de la thyroïde ou de traitements médicamenteux, demander conseil à un professionnel de santé. A conserver au frais, au sec et à l’abri de la lumière
Regulatory points
- Conditions légales
Brassica oleracea L.: L'étiquetage doit comporter un avertissement recommandant aux personnes ayant une hypothyroïdie ou un traitement de la thyroïde de consulter leur médecin.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Vitex agnus-castus L.
Read the warning, when it applies and the studies cited
CHASTE TREE - VITEX AGNUS-CASTUS
Route of administration: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).
Sources cited by Health Canada (4)
- Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
Contraindications
Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).
Sources cited by Health Canada (9)
- Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
- Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
- Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
- Silybum marianum (L.) Gaertn.
Read the warning, when it applies and the studies cited
MILK THISTLE - SILYBUM MARIANUM
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).
Sources cited by Health Canada (2)
- Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
- Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- CYCLAREL Laboratoire Santarel, declared in 2024 : different composition: 1 ingredient(s) added, 1 missing
- CYCLAREL Laboratoire Santarel, declared in 2021, earlier declaration, replaced by the 2026 declaration : different composition: 2 ingredient(s) added, 0 missing
- Cyclarel SANTAREL LTD, declared in 2020, withdrawn from the market : different composition: 3 ingredient(s) added, 1 missing
- CYCLAREL La boratoire Santarel, declared in 2020, withdrawn from the market : different composition: 3 ingredient(s) added, 1 missing
Brand : Laboratoire Santarel
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.